WO1996006603A1 - Polyalkylene oxide containing quaternary ammonium antimicrobial agents - Google Patents
Polyalkylene oxide containing quaternary ammonium antimicrobial agents Download PDFInfo
- Publication number
- WO1996006603A1 WO1996006603A1 PCT/US1995/009724 US9509724W WO9606603A1 WO 1996006603 A1 WO1996006603 A1 WO 1996006603A1 US 9509724 W US9509724 W US 9509724W WO 9606603 A1 WO9606603 A1 WO 9606603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- substituted
- formulation
- aromatics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/38—Cationic compounds
- C11D1/62—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
Definitions
- This invention is directed to ophthalmic compositions comprising quaternary ammonium compounds containing a polyalkylene oxide moiety. Some of the compounds are new. These polymeric compounds are useful as antimicrobial agents. The invention is also directed to exact molecular weight quaternary ammonium compounds containing a polyalkylene oxide moiety.
- the antimicrobial activity of quaternary ammonium compounds is known; see for example, Petrocci, et al., Dev. Ind. Micro., 20, Chapter 1 (1978); Petrocci, Disinfection, Sterilization aid Preservation, Third Edition, Chapter 14 (1983); Hugo, et al., Principles and Practices of Disinfection, Preservation and Sterilizotion, Chapter 2 (1982).
- U.S. Patent No. 4,567,302 and EP 214,850 disclose quaternary ammonium compounds which contain polyalkylene oxide units; however, neither disclose the compounds of the present invention.
- U. S. Patent No. 4,110,263 discloses biquatemary ammonium compounds useful in cleansing compositions in combination with a detergent. The compounds are useful for shampoos, skin cleansers, baby and bubble baths.
- WO 91/09522 discloses ophthalmic compositions useful in the care of contact lenses. The compositions contain a quaternary ammonium substituted matrix material selected from proteinaceous materials, carbohydrate materials, or mixtures thereof. Unlike the compounds used in the present invention, the quaternary ammonium groups are
- EP 0153 435 A1 discloses hair care compositions containing diquatemary nitrogen polyethylene glycol derivatives.
- CA 110(3), 23322K discloses the preparation of certain pentane diammonium debiomides as antimicrobial agents.
- Polymeric disinfectants in general, have shown weak antifungal activity although they exhibit remarkable antimicrobial activity against other organisms.
- This invention discloses the use of particular polymeric disinfecting agents which have a broad spectrum of antimicrobial activity, including antifungal activity. Summary of the Invention This invention is directed to contact lens care formulations and ophthalmic formulations comprising certain quaternary ammonium compounds containing a polyalkylene oxide moiety.
- the compounds are antimicrobials and are useful as disinfecting agents and preservatives.
- the invention is also directed to methods for using the compounds to disinfect contact lenses and preserve contact lens care solutions and ophthalmic formulations.
- Detailed Description of Preferred Embodiments The ophthalmic formulations of this invention contain quaternary ammonium compounds containing a polyalkylene oxide moiety of the following
- R 2 and R 3 are the same, or different, and are selected from the group: C 1 -C 20 alkyl, benzyl and substituted benzyls, aromatics and substituted aromatics and cycloalkyl and substituted cycloalkyls;
- Q and E are the same, or different, and are selected from the group: H, C 1 -C 20 alkyl, C 2 -C 6 alkene, benzyl and substituted benzyls, aromatics and substituted aromatics, cycloalkyl and substituted cycloalkyls; heteroatom containing long alkyl chain, silane and siloxane; but, either Q and/or E must contain an alkyl structure of at least a C 5 alkyl, but not more than a C 20 alkyl moiety;
- Z has the following structure:
- R and R' are different and can be H, methyl or ethyl
- n 1-4
- Preferred compounds within the above defined structure have the following formulas:
- the compounds are formulated into disinfecting and storage solutions for all types of contact lenses.
- the formulations can also be used as preserved saline solutions for rinsing and as an in the eye drop to rehydrate a lens and/or to soothe the eye.
- the compounds are also useful as preservatives in ophthalmic formulations other than lens care solutions, such as, ophthalmic pharmaceutical formulations.
- the compounds are present in the formulations at concentrations of about 0.0001 to 1.0 weight percent (wt. %), preferably 0.0001 to 0.1 wt. %, and most preferably about 0.0005 to 0.01 wt. %
- the compositions may contain other ingredients known to those skilled in the art of contact lens care solutions and/or ophthalmic pharmaceutical formulations.
- the compounds of the present invention overcome some problems associated with prior antimicrobial compounds, such as benzalkonium chloride (BAC). Specifically, the use of BAC has the potential for inducing a toxic response, particularly after long term use. Without intending to be bound by any theory it is believed that the polyalkylene oxide moieties of the quaternary ammonium compounds of the present invention are responsible for the compounds producing a relatively low toxic response in ophthalmic applications. It is also believed that the polyalkylene moieties decrease the interaction of the quaternary ammonium group of the compounds with other compounds of the ophthalmic formulations or the environment to which the ophthalmic formulation is applied.
- BAC benzalkonium chloride
- the electron donor properties of the polyalkylene oxide moiety interact with the quaternary ammonium group (an electron acceptor group) thereby decreasing the interaction of the quaternary ammonium group with other compounds.
- the polyalkylene oxide containing polymers have been used to reduce the interaction of polymers with biomaterials. The following data shows that the above compounds are active even in the presence of the sodium salt of polystyrene sulfonate while marked reduction in antimicrobial activity was observed from BAC under the same experimental conditions.
- the above formulations also contain the sodium salt of polystyrene sulfonate.
- Two general schemes were employed to synthesize the compounds of the present invention.
- the monoquat compounds [A] were prepared starting from an aromatic substituted polyethylene oxide. An excellent starting compound was found to be p - nonylphenol polyethylene oxide. This compound was obtained as surfonic N-120 and N- 60.
- the SURFONIC ® N series of compounds, available from Texaco, are reaction products or adducts of nonylphenol and ethylene oxides. This was reacted with thionyl chloride and then converted to a tertiary amine and then the quaternary ammonium compound according to the following general scheme.
- diquat compounds such as [B] and [C] were prepared starting with hydroxy terminated polyalkylene oxides in the following general scheme of reactions.
- the degree of polymerization is an expression of the number of structural units in a given polymer molecule. This number actually represents the average degree of polymerization as all the molecules will not have the same n.
- This invention is also directed to the use of polymers with an exact molecular weight, that is, no distribution of molecular weight. New procedures for making the exact molecular weight polymers are set forth below.
- octaethylene glycol was synthesized by following the procedure reported in J. Org. Chem., 57, 6678, (1992) (Erik M. D. Keegstra, et al.): trityl chloride was reacted with excess diethylene glycol to make a monotritylated diethylene glycol intermediate (yield: 87%) followed by reaction of two equivalents of the monotritylated compound with one equivalent of tetraethylene glycol di-p -tosylate to form the ditritylated octaethylene glycol intermediate (yield: 95%) which was then converted to octaethylene glycol by hydro genolysis with hydrogen and palladium on charcoal catalyst (purity: 97.2%, by GC yield: 90%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Ophthalmic compositions of quaternary ammonium compounds containiing a polyalkylkene oxide moiety useful as antimicrobial agents are disclosed. Methods for using the compositions are also disclosed. In addition, polymers with no molecular weight distribution are disclosed.
Description
Polyalkylene Oxide Containing Quaternary Ammonium Antimicrobial Agents
Background of the Invention This invention is directed to ophthalmic compositions comprising quaternary ammonium compounds containing a polyalkylene oxide moiety. Some of the compounds are new. These polymeric compounds are useful as antimicrobial agents. The invention is also directed to exact molecular weight quaternary ammonium compounds containing a polyalkylene oxide moiety. The antimicrobial activity of quaternary ammonium compounds is known; see for example, Petrocci, et al., Dev. Ind. Micro., 20, Chapter 1 (1978); Petrocci, Disinfection, Sterilization aid Preservation, Third Edition, Chapter 14 (1983); Hugo, et al., Principles and Practices of Disinfection, Preservation and Sterilizotion, Chapter 2 (1982). In addition, U.S. Patent No. 4,567,302 and EP 214,850 disclose quaternary ammonium compounds which contain polyalkylene oxide units; however, neither disclose the compounds of the present invention. U. S. Patent No. 4,110,263 discloses biquatemary ammonium compounds useful in cleansing compositions in combination with a detergent. The compounds are useful for shampoos, skin cleansers, baby and bubble baths. WO 91/09522 discloses ophthalmic compositions useful in the care of contact lenses. The compositions contain a quaternary ammonium substituted matrix material selected from proteinaceous materials, carbohydrate materials, or mixtures thereof. Unlike the compounds used in the present invention, the quaternary ammonium groups are
substituents on a matrix material backbone rather than being part of the polyalkelene oxide polymer backbone. EP 0153 435 A1 discloses hair care compositions containing diquatemary nitrogen polyethylene glycol derivatives. CA 110(3), 23322K discloses the preparation of certain pentane diammonium debiomides as antimicrobial agents. Polymeric disinfectants, in general, have shown weak antifungal activity although they exhibit remarkable antimicrobial activity against other organisms. This invention
discloses the use of particular polymeric disinfecting agents which have a broad spectrum of antimicrobial activity, including antifungal activity. Summary of the Invention This invention is directed to contact lens care formulations and ophthalmic formulations comprising certain quaternary ammonium compounds containing a polyalkylene oxide moiety. The compounds are antimicrobials and are useful as disinfecting agents and preservatives. The invention is also directed to methods for using the compounds to disinfect contact lenses and preserve contact lens care solutions and ophthalmic formulations. Detailed Description of Preferred Embodiments The ophthalmic formulations of this invention contain quaternary ammonium compounds containing a polyalkylene oxide moiety of the following
general formula:
w = 0-10;
y = 0 or 1;
R2 and R3 are the same, or different, and are selected from the group: C1-C20 alkyl, benzyl and substituted benzyls, aromatics and substituted aromatics and cycloalkyl and substituted cycloalkyls; Q and E are the same, or different, and are selected from the group: H, C1-C20 alkyl, C2-C6 alkene, benzyl and substituted benzyls, aromatics and substituted aromatics, cycloalkyl and substituted cycloalkyls; heteroatom containing long alkyl chain, silane and siloxane; but, either Q and/or E must contain an alkyl structure of at least a C5 alkyl, but not more than a C20 alkyl moiety; Z has the following structure:
[(CH2-CH(R)- O)n -(CH2-CH(R')-O)m]x
wherein:
R and R' are different and can be H, methyl or ethyl;
n = 1-4
m = 0-4
x = 1-50; and
A- is a pharmaceutically acceptable anion, e.g. Cl-, Br-, I-, CH3(C=O)-O-, etc. Preferred compounds within the above defined structure have the following formulas:
The compounds are formulated into disinfecting and storage solutions for all types of contact lenses. The formulations can also be used as preserved saline solutions for rinsing and as an in the eye drop to rehydrate a lens and/or to soothe the eye. The compounds are also useful as preservatives in ophthalmic formulations other than lens care solutions, such as, ophthalmic pharmaceutical formulations. The compounds are present in the formulations at concentrations of about 0.0001 to 1.0 weight percent (wt. %), preferably 0.0001 to 0.1 wt. %, and most preferably about 0.0005 to 0.01 wt. % The compositions may contain other ingredients known to those skilled in the art of contact lens care solutions and/or ophthalmic pharmaceutical formulations. The compounds of the present invention overcome some problems associated with prior antimicrobial compounds, such as benzalkonium chloride (BAC). Specifically, the use of BAC has the potential for inducing a toxic response, particularly after long term use.
Without intending to be bound by any theory it is believed that the polyalkylene oxide moieties of the quaternary ammonium compounds of the present invention are responsible for the compounds producing a relatively low toxic response in ophthalmic applications. It is also believed that the polyalkylene moieties decrease the interaction of the quaternary ammonium group of the compounds with other compounds of the ophthalmic formulations or the environment to which the ophthalmic formulation is applied. It is postulated that the electron donor properties of the polyalkylene oxide moiety interact with the quaternary ammonium group (an electron acceptor group) thereby decreasing the interaction of the quaternary ammonium group with other compounds. Furthermore, the polyalkylene oxide containing polymers have been used to reduce the interaction of polymers with biomaterials. The following data shows that the above compounds are active even in the presence of the sodium salt of polystyrene sulfonate while marked reduction in antimicrobial activity was observed from BAC under the same experimental conditions.
Survival Count of P. aeruginosa
in the Presence of BAC and Compound B*
*
The above formulations also contain the sodium salt of polystyrene sulfonate.
Two general schemes were employed to synthesize the compounds of the present invention. The monoquat compounds [A] were prepared starting from an aromatic substituted polyethylene oxide. An excellent starting compound was found to be p - nonylphenol polyethylene oxide. This compound was obtained as surfonic N-120 and N- 60. The SURFONIC® N series of compounds, available from Texaco, are reaction products or adducts of nonylphenol and ethylene oxides. This was reacted with thionyl chloride and then converted to a tertiary amine and then the quaternary ammonium compound according to the following general scheme.
The diquat compounds such as [B] and [C] were prepared starting with hydroxy terminated polyalkylene oxides in the following general scheme of reactions.
Example 1 Synthesis of Compound A (n=10) Surfonic N-120 (6.55 g, 0.01 moles, from Texaco, Austin, TX) was reacted with 1.38 g (0.01 moles) of thionylchloride and 0.88 g (0.01 moles) of pyridine in 150 mL of toluene under reflux condition for 6 hrs. A precipitate was formed. The decanted organic layer was concentrated in vacuo and dissolved in chlorofoπn (80 mL). This organic solvent was washed with satd. NaCl (10 mL X 3), dried over anhydrous Na2SO4, and evaporated to leave a liquid material (6 g). IR indicated no OH groups in the molecule, The above chlorinr compound (5 g, 0.0076 moles) was reacted with an excess amount of N,N-dimethylamine in 30 mL of dry THF (dried over LAH) under the pressure at 70°C for 24 hrs. and filtered. The filtrate was concentrated in vacuo and dissolved in chloroform (50 mL). This was washed with saturated NaCl solution and evaporated in vacu to leave the corresponding tertiary amine (5 g, 100% yield). NMR spectrum shows singlet at 2.3 ppm for N(CH3)2. The tertiary amine (2.27 g, 0.0034 mole) was then reacted with p-chlorobenzyl chloride (0.54 g, 0.0034 mole) in 20 mL of isopropanol under reflux conditions for 7 hrs. The concentrated reaction mixture was applied on a preparative C18 reverse phase column with acetonitrile:H2O (70:30) was used as an eluent. The corresponding fraction was collected and concentrated in vacuo to leave 1.5 g (51.9% yield) of the product:
Elemental Analysis: calcd. for C48H83 Cl12NO12•1 1/2 H2O:C, 59.80; H, 8.99; N, 1.45; Cl, 7.35; O, 19.91. Found: C, 59.90; H, 8.91; N, 1.61 NMR (CDCl3) δ 7.55 and 6.75 (2d, 4, C6H4), 7.3-7.0 (broad, 4, C6H4), 5.0 (s, 2,∅-CH2), 4.1-3.4 (48, OCH2CH2 ), 3.3 (s, 6, N- CH3) and 1.7-0.4 (19,(CΗ2)8CH3).
Example 2 Synthesis of Compound B (n=6, m=11, A=Cl) By following the same procedure as described for the synthesis of A(n=10) with polyethylene oxide (molecular weight 400) 20 g (0.05 moles) was reacted with 6.6 g (0.055 moles) of thionyl chloride and 4.9 g (0.055 moles) of pyridine in 200 mL of toluene 20 g. (100% yield) of the product is obtained. No appreciable amount of hydroxyl group was detected by IR spectrum. The above dichloro compound (4.0 g, 0.01 moles) was reacted with an excess amount of N,N-dimethyldodecyl amine at 130°C for 24 hrs with stirring to afford 7.0 g (83.9% yield) of the quat compound: Elemental Analysis: Calcd. for C42H86N2O9Cl2 (834.05)•H2O:C, 59.21; H, 10.41; N, 3.29. Found: C, 59.21; H, 10.70; N, 3.11. NMR (CDCl3) δ 4.0-3.4 (broad, 40, OCH2CH2 and N-CH2), 3.35 (s, 6, N-CH), 1.7 (broad, 4, - N-CH2CH2), 1.4-1.1 (app 25, 36, (CH2)n), and 0.8 (t, 6, -CH2-CH3). Example 3 Synthesis of Compound C3 (n=6) The polyethylene oxide (MW 400) dichloro compound (2.45 g, 0.0061 moles) was reacted with 3.78 g (0.0127 moles) of n-(N,N-dimethylethyl )-tetradecanoyl amide
(synthesized from myristoyl chloride and N,N-dimethylethylenediamine) at 125°C for 6 hrs. Purification by ethyl ether afforded 1.8 g (30% yield) of the desired product:
Elemental Analysis: Calcd for C54H112N4O10C l2 (1048.36C1 H2O C, 60.82; H, 10.79; N, 5.25. Found: C, 60.62; H, 10.83; N, 5.20. NMR (CDCl3) δ 8.7 (broad s, 2, N-H), 3.8 (m, 44, CH2CH2O and N+-CH2), 3.4 (d, 12, N-CH3), 2.2 (t, 4, CH2-C(=O)-) , 1.6 (t, 4, C(=O)CH2CH2), 1.2 (s, 30, (CH2)10-CH3) and 0.9 (t, 6, CH3).
Example 4 Synthesis of Compound C2 (n=6) Following the same procedure as described for the synthesis of compound C3 with 3.0 g (0.012 moles) of N-(N,N-dimethylethyl)-nonanoylamide (synthesizsed from nonanoyl chloride and N,N-dimethylethylene diamine) and 1.57 g (0.0038 moles) of polyethylene oxide (m.w. 400) - dichlo compounds, 2.2 g (59% yield) of the product was obtained. Elemental Analysis: Calcd for C44H92N4O9Cl2 : C, 59.29; H, 10.40; N, 6.29: Found: C, 59.37; H, 10.71; N, 6.42. NMR (CDCl3) δ 8.7 (broad s, 2, NH), 3.8 (m, 40, CH2CH2O- and N+-CH2); 3.4 (s, 12, N+CH3), 0.9 (t, 6, CH3), 2.3 (t, 4, C-CH2), 1.6 (m, 4, N- CH2CH2), 1.3 (broad s, 24, CH3- (CH2)) , 0.9 (s, 6, CH3). Example 5 Synthesis of Compound Cl (n=6) The polyethylene oxide (molecular weight 400) dichloro compound (5.1 g, 0.013 moles) was reacted with an excess amount of dimethylamine in 20 mL of tetrahydrofuran at 85°C for 16 hrs under pressure and concentrated in vacuo to remove the solvent. The remaining material was dissolved in ethylacetate and washed with saturated NaCl
Solution. This reaction yielded 2.9 g (57%) of the desired tetramethyl-diamine cornpound. The structure has confirmed by NMR and IR spectra. The above compound (2.3 g, 0.0058 moles) was reacted with (mp)- dimethylhexylsilylethylbenzyl chloride (3.9 g, 0.0131 moles) in 40 mL of isopropanol under reflux condition for 6 hrs. This reaction afforded 2.9 g (50.9% yield) of the desired product. Elemental Analysis: Calcd for C56H106N2O8 Si2Cl2 (1062.50)•1 H2O:C, 62.24; H, 10.07; N, 2.59. Found: C, 62.49; H, 10.24; N, 2.67. NMR (CDCl3) δ 7.4 (m, 8, -∅-), 5.0 (s, 4, -∅-CH2-N+), 3.6 (m, 36, OCH2CH2) 3.4 (s, 12, N+CH3) .
The degree of polymerization, represented in the above compounds by n, is an expression of the number of structural units in a given polymer molecule. This number actually represents the average degree of polymerization as all the molecules will not have the same n. This invention is also directed to the use of polymers with an exact molecular weight, that is, no distribution of molecular weight. New procedures for making the exact molecular weight polymers are set forth below.
The following examples are directed to synthesis of exact molecular weight compounds. Coπφounds B4 and B6 are most preferred.
Example 6
Synthesis of Exact Molecular Weight PEO Spacer Compounds
16.00 g (82.4 mM) of tetraethylene glycol was reacted with 16.30 g (206 mM) of pyridine and 24.50 g (206 mM) of thionyl chloride in dry chloroform (200 mL) at 65°C for 5 hrs. The reaction was neutralized by addition of aq NaHCO3 and the organic phase washed with water (2 X 25 mL) then dried (MgSo 4). The filtrate was concentrated and the residue distilled under reduced pressure (bp10 84-85°C) to provide 15.63 g (82%) of tetraethylene glycol dichloride as a clear oil. 1.04 g (4.5 mM) of tetraethylene glycol dichloride was reacted with 2.44 g (10.12 mM) of N,N -dimethylteradecylamine in 0.3 g
of DMSO and heated at 100°C for 18 hrs. Upon cooling the solidified reaction product was crystallized from ethyl acetate followed by recrystallization from ethyl acetate and ethanol to give 0.9 g (28%) of B1 as white crystals, mp 106-108°C. 1H NMR (200 MHz, CDCl3): δ 4.1-3.6 (broad, 20 H, OCH2CH2, NCHz), 3.45 (S, 12 H, N-CH3), 1.72 (broad, 4 H, NCH2CH2), 1.4-1.2 (broad, 44 H, (CH2)n), 0.88 (t, 6 H, -CH2CH3). Anal. Calcd for C40H86CI2N2O3•(1.25 H2O): C, 65.23; H, 12.14; N, 3.92; Found: C, 65.29; H, 12.08; N, 3.84. b) Compound B3
15.00 g (53.1 mM) of hexaethylene glycol was reacted with 14.10 g (178 mM) of pyridine and 20.8 g (175 mM) of thionyl chloride in dry chloroform (200 mL) at 65°C for 5 hrs. The reaction was neutralized by addition of aq NaHCO3 and the organic phase washed with water (2 X 25 mL) then dried (MgSO4). The filtrate was concentrated and the residue distilled under reduced pressure (bp10 147-152°C) to provide 11.63 g (69%) of hexaethylene glycol dichloride as a clear oil. 4.8 g (15.0 mM) of hexaethylene glycol dichloride was reacted with 8.81 g (36.5 mM) of N,N-dimethyltetradecylamine in 2 g of DMSO and heated at 125°C for 15 hrs. The solidified reaction product was dissolved in ethyl acetate and precipitated with hexane (X 3) to remove DMSO then crystallized from ethyl acetate followed by recrystallization from ethyl acetate and ethanol to give 6.19 g (51%) of B3 as white crystals. 1H NMR (200 MHz, D2O ): δ 3.96-3.32 (broad, 28 H, OCH2CH2, NCH2-), 3.13, 3.09 (2S, 12 H, N-CH3), 1.75 (broad, 4 H, NCH2CH2-), 1.4-1.2 (broad, 44 H, (CH2)n), and 0.86 (t, 6 H, CH2CH3 ). c) Compound B2
10.48 g (53.9 mM) of tetraethylene glycol was reacted with 10.28 g (130 mM) of pyridine and 27.0 g (130 mM) of thionyl bromide in dry chloroform (100 mL) at 70°C for 5 hrs. The reaction was neutralized by addition of aq NaHCO3 and the organic phase washed with water (2 X 25 mL) then dried (MgSO4). The filtrate was concentrated and a resulting sulfur precipitate removed by addition of chloroform and filtration through Celite. The filtrate was concentrated and the residue distilled under reduced pressure (bp10 100°C) to provide 7.71 g (45%) of tetraethylene glycol dibromide as an amber oil. 2.20 g (6.88 mM) of tetraethylene glycol dibromide was reacted with 3.65 g (15.1 mM) of N,N-
dimethylteradecylamine in 0.5 g of DMSO at 90°C for 15 hrs. The solidified reaction product was crystallized twice from ethyl acetate to give 3.93 g (71%) of B2 as amber crystals. 1H NMR (200 MHz, D2O): δ 4.0-3.4 (broad, 20 H, OCH2CH2, NCH2), 3.19 (S, 12 H, N-CH3), 1.8 (broad, 4 H, NCH2CH2-), 1.4-1.2 (broad, 44 H, (CH2)n), and 0.86 (t, 6 H, -CH2CH3). Anal. Calcd for C40H86Br2N2O3•(0.5 H2O): C, 59.17; H, 10.80; N, 3.45; Found: C, 59.40; H, 10.54; N, 3.52. d) Compound B4
9.44 g (33.4 mM) of hexaethylene glycol was reacted with 6.38 g (80.7 mM) of pyridine and 16.76 g (80.6 mM) of thionyl bromide in dry chloroform (100 mL) at 65°C for 3 hrs. The reaction was neutralized by addition of water and stirred for 30 minutes followed by washing of the organic phase with water until slightly acidic (2 X 25 mL, pH = 4-5). The organic phase was dried (MgSO4), the filtrate concentrated and a resulting sulfur precipitate removed by addition of methanol and filtration through Celite (X 2). The filtrate was concentrated and the residue was dried in vacuo to provide 8.85 g (65%) of hexaethylene glycol dibromide as an amber oil. 2.26 g (5.53 mM) of hexaethylene glycol dibromide was reacted with 2.94 g (12.2 mM) of N,N- dimethylteradecylamine in 0.6 g of DMSO at 90°C for 15 hrs. The solidified reaction product was crystallized from ethyl acetate followed by recrystallization from ethyl acetate and ethanol to give 3.17 g (64%) of B4 as white crystals, mp 95-97°C. 1H NMR (200 MHz, DA: δ 4.0-3.4 (broad, 28 H, OCH2CH2, NCH2-), 3.15 (S, 12 H, N-CH3), 1.78 (broad, 4 H, NCH2CH2-), 1.4-1.2 (broad, 44 H, (CH2)n), and 0.86 (t, 6 H, -CH2CH3). Anal. Calcd for C44H94Br2N2O5: C, 59.31; H, 10.63; N, 3.14; Found: C, 59.20; H, 10.59; N, 3.11. e) Compound B5
The synthesis of octaethylene glycol was performed by following the procedure reported in J. Org. Chem., 57, 6678, (1992) (Erik M. D. Keegstra, et al.): trityl chloride was reacted with excess diethylene glycol to make a monotritylated diethylene glycol intermediate (yield: 87%) followed by reaction of two equivalents of the monotritylated compound with one equivalent of tetraethylene glycol di-p -tosylate to form the ditritylated octaethylene glycol intermediate (yield: 95%) which was then converted to octaethylene glycol by hydro genolysis with hydrogen and palladium on charcoal catalyst (purity:
97.2%, by GC yield: 90%). Overall yield was 74% 4.47 g (12.1 mM) of octaethylene glycol was reacted with 2.30 g (29.1 mM) of pyridine and 6.07 g (29.2 mM) of thionyl bromide in dry chloroform (100 mL) at 50°C for 5 hrs. The reaction was neutralized by addition of water (25 mL) and stirred for 30 minutes followed by washing of the organic phase with water until slightly acidic (3 X 20 mL, pH = 4-5). The organic phase was dried (MgSO4), the filtrate concentrated and the resulting sulfur precipitate removed by addition of methanol and filtration through Celite (X 2). The filtrate was concentrated and the residue dried in vacuo to provide 4.41 g (74%) of octaethylene glycol dibromide as an amber oil. 2.91 g (5.86 mM) of octaethylene glycol dibromide was reacted with 3.12 g (12.9 mM) of N,N-dimethyltetra-decylamine in 0.7 g of DMSO at 80°C for 15 hrs. The solidified reaction product was crystallized from ethyl acetate followed by recrystallization from ethyl acetate and ethanol to give 4.0 g (70%) of B5 as white crystals. 1H NMR (200 MHz, D2O ): δ 4.0-3.35 (broad, 36 H, OCH2CH2 NCH2-), 3.15 (S, 12 H, N-CH3), 1.76 (broad, 4 H, NCH-CH2), 1 4-1.2 (broad, 44 H, (CH2)n), 0.86 (t, 6 H, -CH2CH3). Anal, Calcd for C48H102Br2N2O7 : C, 58.88; H, 10.50; N, 2.86; Found: C, 58.56; H, 10.28; N, 2.89. f) Compound B6
1.65 G (4.0 mM) of hexaethylene glycol dibromide was reacted with 1.90 g (8.9 mM) of N,N- dimethylteradecylamine in 0.44 g of DMSO and heated at 80°C for 15 hrs. The solidified reaction product was crystallized from ethyl acetate followed by
recrystallization from ethyl acetate and ethanol to give 1.85 g (55%) of B6 as white crystals, mp 83-85°C. 1H NMR (200 MHz, DA: δ 4.0-3.35 (broad, 28 H, OCH2CH2, NCH2-), 3.15 (S, 12 H, N-CH3), 1.8 (broad, 4 H, NCH2CH2-), 1.4-1.2 (broad, 36 H, (CH2)n), 0.86 (t, 6 H, -CH2C H3). Anal. Calcd for C40H86Br2N2O5: C, 57.54; H, 10.38; N, 3.36; Found: C, 57.68; H, 10.42; N, 3.30.
Log Reduction of 0.001% Compounds*
Example 7
Claims
We claim: 1. A contact lens formulation comprising a compound having the structure:
wherein:
w = 0-10;
y = 0 or 1;
R2 and R3 are the same, or different, and are selected from the group: C1-C20 alkyl, benzyl and substituted benzyls, aromatics and substituted aromatics and cycloalkyl and substituted cycloalkyls; Q and E are the same, or different, and are selected from the group: H, C1-C20 alkyl, C2-C6 alkene, benzyl and substituted benzyls, aromatics and substituted aromatics, cycloalkyl and substituted cycloalkyls; heteroatom containing long alkyl chain, silane and siloxane; but, either Q and/or E must contain an alkyl structure of at least a C5 alkyl, but not more than a C20 alkyl moiety; Z has the following structure: [(CH2-CΗ(R)-O)n-(CH2-CH(R')-O)m]x
wherein:
R and R1 are different and can be H, methyl or ethyl;
n = 1-4
m = 0-4
x = 1-50; and
A- is a pliaπnaceutically acceptable anion.
3. The formulation of Claim 1 wherein the compound is present at a concentration of 0.0001% to 1.0%
4. The formulation of Claim 3 wherein the compound is present at a concentration of 0.0005% to 0.01%.
5. An ophthalmic formulation comprising a compound having the structure
wherein:
w = 0-10;
y = 0 or 1;
R2 and R3 are the same, or different, and are selected from the group: C1-C20 alkyl, benzyl and substituted benzyls, aromatics and substituted aromatics and cycloalkyl and substituted cycloalkyls; Q and E are the same, or different, and are selected from the group: H, C1-C20 alkyl, C2-C6 alkene, benzyl and substituted benzyls, aromatics and substituted aromatics, cycloalkyl and substituted cycloalkyls; heteroatom containing long alkyl chain, silane and siloxane; but, either Q and/or E must contain an alkyl structure of at least a C5 alkyl, but not more than a C20 alkyl moiety; Z has the following structure: [(CH2-CH(R)-O)n-(CH2-CH(R,)-O)m]x wherein:
R and R' are different and can be H, methyl or ethyl;
n = 1-4
m = 0-4
x = 1-50; and
A is a pharmaceutically acceptable anion.
wherein R and n are as defined below:
7. The formulation of Claim 5 wherein the compound is present at a concentration of 0.0001% to 1.0%.
8. The formulation of Claim 7 wherein the compound is present at a concentration of 0.0005% to 0.01%
9. A method for disinfecting a contact lens; which comprises, applying the composition of Claim 1 to the lens.
10. A method for preserving an ophthalmic formulation by adding a compound of Claim 5 to the formulation.
11. A compound of the formula
12. A compound of the formula
C
wherein m is 13, n is 2 and A is Cl having a molecular weight of 714.05.
13. A compound of the formula
14. A compound of the formula
wherein m is 13, n is 4 and A is Cl having a molecular weight of 802.16.
15. A compound of the formula
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU31551/95A AU3155195A (en) | 1994-08-26 | 1995-08-02 | Polyalkylene oxide containing quaternary ammonium antimicrobial agents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29664094A | 1994-08-26 | 1994-08-26 | |
| US08/296,640 | 1994-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996006603A1 true WO1996006603A1 (en) | 1996-03-07 |
Family
ID=23142888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/009724 Ceased WO1996006603A1 (en) | 1994-08-26 | 1995-08-02 | Polyalkylene oxide containing quaternary ammonium antimicrobial agents |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3155195A (en) |
| WO (1) | WO1996006603A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000007634A1 (en) * | 1998-08-06 | 2000-02-17 | Ndt, Inc. | Contact lens and ophthalmic solutions |
| WO2002064715A3 (en) * | 2001-02-13 | 2002-10-03 | Bausch & Lomb | High osmolyte cleaning and disinfection method and solution for contact lenses |
| JP2004345953A (en) * | 2003-01-16 | 2004-12-09 | Hiroki Koma | New quaternary ammonium salt compound having anti-bacterial activity and method for producing the same |
| WO2010128270A3 (en) * | 2009-05-08 | 2011-03-31 | Halliburton Energy Services, Inc. | Treatment fluids for reduction of water blocks, oil blocks, and/or gas condensates and associated methods |
| US8093352B2 (en) | 2008-08-05 | 2012-01-10 | Alcon Research, Ltd. | Polyalkylene oxide polyquaternary ammonium biocides |
| US8669212B2 (en) | 2009-09-03 | 2014-03-11 | Halliburton Energy Services, Inc. | Fluorosurfactants and treatment fluids for reduction of water blocks, oil blocks, and/or gas condensates and associated methods |
| US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
| US9492582B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| US9492581B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110263A (en) * | 1977-06-17 | 1978-08-29 | Johnson & Johnson Baby Products Company | Mild cleansing compositions containing alkyleneoxylated bisquaternary ammonium compounds |
| US4567302A (en) * | 1984-07-20 | 1986-01-28 | Angus Chemical | Polymeric quaternary ammonium salts possessing antimicrobial activity and methods for preparation and use thereof |
| WO1991009522A1 (en) * | 1990-01-05 | 1991-07-11 | Allergan, Inc. | Ophthalmic compositions and methods for preserving and using same |
| US5242684A (en) * | 1991-10-25 | 1993-09-07 | Isp Investments Inc. | Antimicrobial, low toxicity, non-irritating composition comprising a blend of bis-quaternary ammonium compounds coprecipitated with a copolymer of vinylpyrrolidone and an acrylamido or vinyl quaternary ammonium monomer |
-
1995
- 1995-08-02 AU AU31551/95A patent/AU3155195A/en not_active Abandoned
- 1995-08-02 WO PCT/US1995/009724 patent/WO1996006603A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110263A (en) * | 1977-06-17 | 1978-08-29 | Johnson & Johnson Baby Products Company | Mild cleansing compositions containing alkyleneoxylated bisquaternary ammonium compounds |
| US4567302A (en) * | 1984-07-20 | 1986-01-28 | Angus Chemical | Polymeric quaternary ammonium salts possessing antimicrobial activity and methods for preparation and use thereof |
| WO1991009522A1 (en) * | 1990-01-05 | 1991-07-11 | Allergan, Inc. | Ophthalmic compositions and methods for preserving and using same |
| US5242684A (en) * | 1991-10-25 | 1993-09-07 | Isp Investments Inc. | Antimicrobial, low toxicity, non-irritating composition comprising a blend of bis-quaternary ammonium compounds coprecipitated with a copolymer of vinylpyrrolidone and an acrylamido or vinyl quaternary ammonium monomer |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1336415A3 (en) * | 1998-08-06 | 2004-07-28 | NDT, Inc. | Contact lens and ophthalmic solutions |
| WO2000007634A1 (en) * | 1998-08-06 | 2000-02-17 | Ndt, Inc. | Contact lens and ophthalmic solutions |
| US6790816B2 (en) | 1999-09-24 | 2004-09-14 | Bausch & Lomb Incorporated | High osmolyte cleaning and disinfection method and solution for contact lenses |
| US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
| US10595532B2 (en) | 2000-11-08 | 2020-03-24 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
| US10064410B2 (en) | 2000-11-08 | 2018-09-04 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
| US9585394B2 (en) | 2000-11-08 | 2017-03-07 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
| US9492581B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| US9492582B2 (en) | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| WO2002064715A3 (en) * | 2001-02-13 | 2002-10-03 | Bausch & Lomb | High osmolyte cleaning and disinfection method and solution for contact lenses |
| JP2004345953A (en) * | 2003-01-16 | 2004-12-09 | Hiroki Koma | New quaternary ammonium salt compound having anti-bacterial activity and method for producing the same |
| US8093352B2 (en) | 2008-08-05 | 2012-01-10 | Alcon Research, Ltd. | Polyalkylene oxide polyquaternary ammonium biocides |
| US8101556B2 (en) | 2009-05-08 | 2012-01-24 | Halliburton Energy Services, Inc. | Treatment fluids for reduction of water blocks, oil blocks, and/or gas condensates and associated methods |
| WO2010128270A3 (en) * | 2009-05-08 | 2011-03-31 | Halliburton Energy Services, Inc. | Treatment fluids for reduction of water blocks, oil blocks, and/or gas condensates and associated methods |
| US8772204B2 (en) | 2009-09-03 | 2014-07-08 | Halliburton Energy Services, Inc. | Fluorosurfactants and treatment fluids for reduction of water blocks, oil blocks, and/or gas condensates and associated methods |
| US8669212B2 (en) | 2009-09-03 | 2014-03-11 | Halliburton Energy Services, Inc. | Fluorosurfactants and treatment fluids for reduction of water blocks, oil blocks, and/or gas condensates and associated methods |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3155195A (en) | 1996-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3353423B2 (en) | New polymeric antimicrobial agents and their use in pharmaceutical compositions | |
| EP0731714B1 (en) | Use of polyethylene oxide-containing polymeric quaternary ammonium compounds in pharmaceutical compositions | |
| JPS6156159A (en) | Antibacterial polymerizable quaternary ammonium salt, manufacture and use | |
| WO1996006603A1 (en) | Polyalkylene oxide containing quaternary ammonium antimicrobial agents | |
| EP0359442B1 (en) | Mono-iodopropargyl esters of dicarboxylic anhydrides and their use as antimicrobial agents | |
| CA2929560A1 (en) | Polycationic amphiphiles as antimicrobial agents | |
| US5512597A (en) | Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials | |
| US4954636A (en) | Antimicrobial polymeric bisbiguanides | |
| US5399737A (en) | Quaternary ammonium siloxane compounds and methods for their use | |
| US6051611A (en) | Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobias | |
| US5741886A (en) | End-capped polymeric biguanides | |
| KR970702287A (en) | TRUNUCLEAR CATIONIC PLATINUM COMPLEXES HAVING ANTITUMOR ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. The present invention relates to a cationic platinum complex having triple- | |
| AU2004297269B2 (en) | Use of bis-amines to enhance the antimicrobial activity of aqueous compositions | |
| KR100278220B1 (en) | Polyionic Polymer and Polyionic Sterilizing Algae | |
| EP0410976A1 (en) | Heat stable quaternized lactams having oxylated sulfur anions | |
| US4073924A (en) | Hydantoin derivatives and broad spectrum bactericidal/fungicidal compositions thereof | |
| JPH0613464B2 (en) | Novel amphoteric compound, method for producing the compound, and disinfectant containing the compound as an active ingredient | |
| US4107313A (en) | α,α-Bis-[4-(R-amino)-1-pyridinium]xylenes and antibacterial and antifungal uses | |
| EP3280760B1 (en) | Cationic compounds and their use as antimycotic and antimicrobial agents | |
| EP1156030A1 (en) | Novel quaternary ammonium salt and process for the preparation thereof | |
| RU2272045C1 (en) | Polydiallylamines and disinfecting agent comprising thereof | |
| JPH09143186A (en) | Quaternary ammonium group-containing disiloxane compound and antimicrobial algaecide | |
| JP3476854B2 (en) | Polycationic fungicide | |
| AU712908B2 (en) | Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials | |
| US4924006A (en) | N-pyrrolidonyl alkyl amino 1,3,4-butanetriol compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |